Education
About Us
Working with TipRanks
Follow Us
TG Therapeutics (TGTX)
:TGTX
Total Valuation
TG Therapeutics has a market cap or net worth of $6.08B. The enterprise value is $1.58B.
Market Cap$6.08B
Enterprise Value$1.58B
Share Statistics
TG Therapeutics has 158,755,040 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding158,755,040
Owned by Insiders9.76%
Owned by Institutions11.52%
Financial Efficiency
TG Therapeutics’s return on equity (ROE) is 0.11 and return on invested capital (ROIC) is 7.84%.
Return on Equity (ROE)0.11
Return on Assets (ROA)0.04
Return on Invested Capital (ROIC)7.84%
Return on Capital Employed (ROCE)0.09
Revenue Per Employee934.67K
Profits Per Employee66.43K
Employee Count352
Asset Turnover0.57
Inventory Turnover0.35
Valuation Ratios
The current PE Ratio of TG Therapeutics is 187.06. TG Therapeutics’s PEG ratio is 0.18.
PE Ratio187.06
PS Ratio0.00
PB Ratio-1.05
Price to Fair Value19.67
Price to FCF-9.09
Price to Operating Cash Flow-9.09
PEG Ratio0.18
Income Statement
In the last 12 months, TG Therapeutics had revenue of 329.00M and earned 23.38M in profits. Earnings per share was 0.16.
Revenue329.00M
Gross Profit290.52M
Operating Income41.93M
Pretax Income25.59M
Net Income23.38M
EBITDA49.90M
Earnings Per Share (EPS)0.16
Cash Flow
In the last 12 months, operating cash flow was -61.02M and capital expenditures -70.00K, giving a free cash flow of -61.09M billion.
Operating Cash Flow-61.02M
Free Cash Flow-61.09M
Free Cash Flow per Share-0.38
Dividends & Yields
TG Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.56
52-Week Price Change125.80%
50-Day Moving Average37.42
200-Day Moving Average31.76
Relative Strength Index (RSI)51.03
Average Volume (3m)2.45M
Important Dates
TG Therapeutics upcoming earnings date is Aug 5, 2025, TBA Not Confirmed.
Last Earnings DateMay 5, 2025
Next Earnings DateAug 5, 2025
Ex-Dividend Date―
Financial Position
TG Therapeutics as a current ratio of 6.25, with Debt / Equity ratio of -5.44%
Current Ratio6.25
Quick Ratio5.03
Debt to Market Cap0.06
Net Debt to EBITDA1.49
Interest Coverage Ratio1.75
Taxes
In the past 12 months, TG Therapeutics has paid 2.21M in taxes.
Income Tax2.21M
Effective Tax Rate0.09
Enterprise Valuation
TG Therapeutics EV to EBITDA ratio is 89.15, with an EV/FCF ratio of -109.67.
EV to Sales13.52
EV to EBITDA89.15
EV to Free Cash Flow-109.67
EV to Operating Cash Flow-109.79
Balance Sheet
TG Therapeutics has $276.24M in cash and marketable securities with $254.58M in debt, giving a net cash position of -$21.66M billion.
Cash & Marketable Securities$276.24M
Total Debt$254.58M
Net Cash-$21.66M
Net Cash Per Share-$0.14
Tangible Book Value Per Share$1.53
Margins
Gross margin is 90.48%, with operating margin of 12.74%, and net profit margin of 7.11%.
Gross Margin90.48%
Operating Margin12.74%
Pretax Margin7.78%
Net Profit Margin7.11%
EBITDA Margin15.17%
EBIT Margin15.08%
Analyst Forecast
The average price target for TG Therapeutics is $41.60, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$41.60
Price Target Upside11.32% Upside
Analyst ConsensusModerate Buy
Analyst Count5
Revenue Growth Forecast33.54%
EPS Growth Forecast-6.13%